Advertisement

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project

  • Marina E. Cazzaniga
  • E. Ciruelos
  • A. Fabi
  • J. Garcia-Saenz
  • H. Lindman
  • D. Mavroudis
  • C. Schem
  • G. Steger
  • E. Timotheadou
  • K. Zaman
  • V. Torri
  • on behalf of the MACBETH Group
Original Article
  • 97 Downloads

Abstract

Introduction

Despite the large use of nab-paclitaxel as a treatment option in metastatic breast cancer (MBC) across different countries, no definitive data are available in particular clinical situations.

Areas covered

Efficacy, safety and schedule issues concerning available literature on nab-paclitaxel in advanced breast cancer and in specific subgroups of patients have been discussed and voted during an International Expert Meeting. Ten expert specialists in oncology, with extensive clinical experience on Nab-P and publications in the field of MBC have been identified. Six scientific areas of interest have been covered, generating 13 specific Statements for Nab-P, after literature review. For efficacy issues, a summary of research quality was performed adopting the GRADE algorithm for evidence scoring. The panel members were invited to express their opinion on the statements, in case of disagreement all the controversial opinions and the relative motivations have been made public.

Expert opinion

Consensus was reached in 30.8% of the Nab-P statements, mainly those regarding safety issues, whereas ones regarding efficacy and schedule still remain controversial areas, requiring further data originated by the literature.

Keywords

Expert meeting Nab-paclitaxel Breast cancer Weekly schedule Neuropathy 

Notes

Funding

None.

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer Oxf Engl 1990 37(13):1590–1598Google Scholar
  2. 2.
    Nyman DW et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23(31):7785–7793CrossRefGoogle Scholar
  3. 3.
    Gradishar WJ et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803CrossRefGoogle Scholar
  4. 4.
    Gradishar WJ et al (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27(22):3611–3619CrossRefGoogle Scholar
  5. 5.
    Bernardo A et al (Oct. 2017) Nab-paclitaxel in advanced HER2-negative breast cancer patients: efficacy and safety beyond clinical trials. Clin Breast Cancer 17(6):433–440CrossRefGoogle Scholar
  6. 6.
    Palumbo R et al (2015) Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Dev Ther 9:2189–2199CrossRefGoogle Scholar
  7. 7.
    Fabi A et al (2015) Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Drug Des Dev Ther 9:6177–6183CrossRefGoogle Scholar
  8. 8.
    Cardoso F et al (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast Edinb Scotl 21(3):242–252CrossRefGoogle Scholar
  9. 9.
    “GRADE handbook (2018) [Online]. http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. Accessed 01 Mar 2018
  10. 10.
    Sharma P et al (2017) Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: combined analysis of two cohorts. Clin Cancer Res 23(3):649–657CrossRefGoogle Scholar
  11. 11.
    Miles DW, Diéras V, Cortés J, Duenne A-A, Yi J, O’Shaughnessy J (2013) First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24(11):2773–2780CrossRefGoogle Scholar
  12. 12.
    Blum JL et al (2007) Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 7(11):850–856CrossRefGoogle Scholar
  13. 13.
    Forero-Torres A et al (2015) TBCRC 019: a phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer. Clin Cancer Res 21(12):2722–2729CrossRefGoogle Scholar
  14. 14.
    Kassam F et al (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9(1):29–33CrossRefGoogle Scholar
  15. 15.
    Untch M et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356CrossRefGoogle Scholar
  16. 16.
    Hammond MEH et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48–e72PubMedGoogle Scholar
  17. 17.
    Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1–2):4–13CrossRefGoogle Scholar
  18. 18.
    Cardoso F et al (2017) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 28(12):3111CrossRefGoogle Scholar
  19. 19.
    Lobbezoo DJA et al (2016) In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol 27(2):256–262CrossRefGoogle Scholar
  20. 20.
    Robertson JFR et al (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet Lond Engl 388(10063):2997–3005CrossRefGoogle Scholar
  21. 21.
    Hortobagyi GN et al (03 2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748CrossRefGoogle Scholar
  22. 22.
    Finn RS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936CrossRefGoogle Scholar
  23. 23.
    Goetz MP et al (2017) MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35(32):3638–3646CrossRefGoogle Scholar
  24. 24.
    Turner NC et al (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373(3):209–219CrossRefGoogle Scholar
  25. 25.
    Sledge GW et al (2017) MONARCH 2: abemaciclib in combination With fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35(25):2875–2884CrossRefGoogle Scholar
  26. 26.
    Piccart M et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol 25(12):2357–2362CrossRefGoogle Scholar
  27. 27.
    NCCN—Evidence-Based Cancer Guidelines, Oncology Drug Compendium, Oncology Continuing Medical Education (2018). https://www.nccn.org/. Accessed 01 Mar 2018
  28. 28.
    Johnson RH, Chien FL, Bleyer A (2013) Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 309(8):800–805CrossRefGoogle Scholar
  29. 29.
    Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271–278CrossRefGoogle Scholar
  30. 30.
    Howell A, Robertson JFR, Vergote I (2003) A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 82(3):215–222CrossRefGoogle Scholar
  31. 31.
    Wilcken N, Hornbuckle J, Ghersi D Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2:CD002747, 2003Google Scholar
  32. 32.
    Bachelot T et al (Aug. 2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718–2724CrossRefGoogle Scholar
  33. 33.
    Raphael J, Helou J, Pritchard KI, Naimark DM (2017) Palbociclib in hormone receptor positive advanced breast cancer: a cost-utility analysis. Eur J Cancer Oxf Engl 1990 85:146–154CrossRefGoogle Scholar
  34. 34.
    Rugo HS et al (Jul. 2015) Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (alliance). J Clin Oncol Off J Am Soc Clin Oncol 33(21):2361–2369CrossRefGoogle Scholar
  35. 35.
    Biganzoli L et al (Apr. 2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13(4):e148–e160CrossRefGoogle Scholar
  36. 36.
    Crivellari D et al (2007) Breast cancer in the elderly. J Clin Oncol Off J Am Soc Clin Oncol 25(14):1882–1890CrossRefGoogle Scholar
  37. 37.
    Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E (2016) Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG task force. Cancer Treat Rev 43:19–26CrossRefGoogle Scholar
  38. 38.
    Aapro M, Tjulandin S, Bhar P, Gradishar W (2011) Weekly nab-paclitaxel is safe and effective in ≥ 65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast Edinb Scotl 20(5):468–474CrossRefGoogle Scholar
  39. 39.
    Ibrahim NK et al (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019–6026CrossRefGoogle Scholar
  40. 40.
    Liang C et al (2015) The treatment patterns, efficacy, and safety of nab®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. BMC Cancer 15:1019CrossRefGoogle Scholar
  41. 41.
    Cold S, Düring M, Ewertz M, Knoop A, Møller S (2005) Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish breast cancer cooperative group (DBCG). Br J Cancer 93(6):627–632CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Marina E. Cazzaniga
    • 1
    • 2
  • E. Ciruelos
    • 3
  • A. Fabi
    • 4
  • J. Garcia-Saenz
    • 5
  • H. Lindman
    • 6
  • D. Mavroudis
    • 7
  • C. Schem
    • 8
  • G. Steger
    • 9
  • E. Timotheadou
    • 10
  • K. Zaman
    • 11
  • V. Torri
    • 12
  • on behalf of the MACBETH Group
  1. 1.Phase 1 Trials Research Unit and Oncology UnitASST Monza and Milano Bicocca School of MedicineMonzaItaly
  2. 2.Oncology UnitASST MonzaMonzaItaly
  3. 3.Unidad de Cáncer de Mama del Centro Integral Oncológico Clara Campal HM CIOCCMadridSpain
  4. 4.Medical OncologyRegina Elena National Cancer InstituteRomeItaly
  5. 5.Department of Medical OncologyIdISSC. CIBERONC-ISCIII, Hospital Clínico San CarlosMadridSpain
  6. 6.Department of Immunology, Genetics and PathologyUniversity of UppsalaUppsalaSweden
  7. 7.Department of Medical OncologyUniversity Hospital of HeraklionHeraklionGreece
  8. 8.MammazentrumHamburgGermany
  9. 9.Department of Internal Medicine IMedical University of ViennaViennaAustria
  10. 10.Aristotle University of Thessaloniki School of MedicinePapageorgiou Gen. HospitalThessaloníkiGreece
  11. 11.Breast Center, Department of OncologyUniversity Hospital CHUVLausanneSwitzerland
  12. 12.Istituto IRCCS Istituto Mario NegriMilanItaly

Personalised recommendations